- Home
- ZTEK vs DXR Comparison
ZTEK vs DXR Comparison
Compare ZTEK & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | DXR |
|---|---|---|
| Founded | 2008 | 1970 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 71.4M |
| IPO Year | 2022 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | DXR |
|---|---|---|
| Price | $0.63 | $11.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 133.4K | 12.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $7.10 |
| 52 Week High | $1.84 | $14.76 |
Technical Indicators
Market Signals| Indicator | ZTEK | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 42.74 |
| Support Level | $0.55 | $11.31 |
| Resistance Level | $0.75 | $14.02 |
| Average True Range (ATR) | 0.05 | 0.39 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 69.90 | 34.12 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.